Heungkuk Life Insurance announced on July 14 that its "Prostate Cancer Biodegradable Material Injection Surgery Rider" has been granted six months of exclusive use rights by the Korea Life Insurance Association.


Heungkuk Life Insurance Secures Exclusive Use Rights for "Prostate Cancer Treatment Side Effect Prevention Rider" View original image

This rider provides annual coverage for biodegradable material injection surgery, which is performed to reduce potential side effects during prostate cancer radiation therapy. It expands the scope of coverage from the traditional diagnosis and treatment focus of cancer insurance to include the prevention of treatment side effects.


"Prostate cancer biodegradable material injection surgery" is a procedure in which a biodegradable material is injected between the prostate and the adjacent rectum to create a buffer space. This helps prevent side effects such as rectal injury by reducing the impact of radiation on the rectum, and the injected material naturally decomposes in the body after a certain period.


Heungkuk Life Insurance has designed this coverage as part of the main prostate cancer treatment rider, thereby enhancing the overall protection offered throughout the cancer treatment process. As a result, the company expects not only to prevent side effects associated with treatment but also to reduce the financial burden on customers.


Heungkuk Life Insurance explained that, whereas existing insurance products have covered only direct cancer treatments or already occurring side effects, this new rider has been recognized for its distinction and originality by expanding coverage to also include the prevention of side effects that may arise during the treatment process.



A representative from Heungkuk Life Insurance stated, "The granting of exclusive use rights recognizes the originality and advancement of coverage that takes into account the cancer treatment process itself," adding, "We will continue to launch products that reflect treatment environments and customers' coverage needs."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing